PTHLH and ischemia: In order to provide definitive evidence in support of the future evaluation of PTHrP or abaloparatide as a clinically relevant cardioprotective agent, additional experiments are required in which the peptide is administered upon relief of ischemia, both sexes are enrolled, mechanistic endpoints are incorporated, and infarct size (together with indices of left ventricular function) is quantified days to weeks after reperfusion.